Liu Miaowen, Zhu Meiyan, Huang Yingxiong, Wu Jian, Peng Zhenwei, Liang Ying
Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Department of Emergency, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Heliyon. 2024 Apr 24;10(9):e29925. doi: 10.1016/j.heliyon.2024.e29925. eCollection 2024 May 15.
Radiotherapy is an effective treatment for hepatocellular carcinoma (HCC). Recent studies indicated that N7-methylguanosine (m7G)-associated genes are involved in radioresistance and prognosis of HCC. However, the prognostic value and underlying mechanism of m7G-and radiosensitivity-associated genes are still lacking.
The related statistics of HCC were downloaded from The Cancer Genome Atlas (TCGA). M7G- and radiosensitivity-associated genes were screened and evaluated using correlation, differential, univariate, and multivariate analysis. The least absolute shrinkage and selection operator (LASSO) algorithm was used to establish a prognostic model. Prognostic efficacy, functional analysis, immune cell infiltration,and drug sensitivity of the prognostic model were assessed. The ceRNA network was predicted and evaluated through the StarBase database, correlation analysis, expression analysis, and survival analysis.
METTL1, EIF3D, NCBP2, and WDR4 participated in prognosis model construction. The favorable prediction efficiency has been verified in both the training and verification sets. Different risk groups have differences in prognosis outcome, function analysis, immune cell infiltration, and drug sensitivity. NCBP2 can be used to predict the prognosis and has excellent potential in immunotherapy. A prognostic ceRNA network based on the NCBP2/miR-122-5p axis was established.
The prognosis model of m7G- and radiosensitivity-related genes is constructed, and widely used in clinical prognosis, immunotherapy, and drug therapy. NCBP2, as a hub gene, may be a prognostic biomarker for HCC and is related to immunotherapy. Establishing the NCBP2/miR-122-5p axis helps study the mechanism of ceRNA and provides new ideas for finding a new candidate biomarker.
放射治疗是肝细胞癌（HCC）的一种有效治疗方法。最近的研究表明，N7-甲基鸟苷（m7G）相关基因参与了HCC的放射抗性和预后。然而，m7G与放射敏感性相关基因的预后价值及潜在机制仍不明确。
从癌症基因组图谱（TCGA）下载HCC的相关统计数据。使用相关性、差异性、单变量和多变量分析筛选并评估m7G与放射敏感性相关基因。采用最小绝对收缩和选择算子（LASSO）算法建立预后模型。评估预后模型的预后疗效、功能分析、免疫细胞浸润和药物敏感性。通过StarBase数据库、相关性分析、表达分析和生存分析预测并评估ceRNA网络。
METTL1、EIF3D、NCBP2和WDR4参与了预后模型构建。在训练集和验证集中均验证了良好的预测效率。不同风险组在预后结果、功能分析、免疫细胞浸润和药物敏感性方面存在差异。NCBP2可用于预测预后，在免疫治疗方面具有优异潜力。建立了基于NCBP2/miR-122-5p轴的预后ceRNA网络。
构建了m7G与放射敏感性相关基因的预后模型，并广泛应用于临床预后、免疫治疗和药物治疗。NCBP2作为枢纽基因，可能是HCC的预后生物标志物，且与免疫治疗相关。建立NCBP2/miR-122-5p轴有助于研究ceRNA机制，为寻找新的候选生物标志物提供新思路。
